MRI/MRS in neuroinflammation: methodology and applications by Mario Quarantelli
REVIEW ARTICLE
MRI/MRS in neuroinflammation: methodology and applications
Mario Quarantelli1
Received: 21 July 2015 / Accepted: 30 August 2015 / Published online: 10 September 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Neuroinflammation encompasses a wide range
of humoral and cellular responses, not only enabling the
CNS to fight various noxious events, including infections
and trauma, but also playing a critical role in autoimmune
as well as in neurodegenerative diseases. The complex
interactions of immune, endothelial, and neuronal cells that
take place during inflammation require an equivalent
complexity of imaging approaches to be appropriately
explored in vivo. Magnetic Resonance provides several
complementary techniques that allow to study most
mechanisms underlying the brain/immune interaction. In
this review, we discuss the MR approaches to the study of
endothelial activation, blood–brain barrier permeability
alterations, intercellular compartment modifications,
immune cell trafficking, and of metabolic alterations linked
to immune cell activity. The main advantages and limita-
tions of these techniques are assessed, in view of their
exploitation in the clinical arena, where the complemen-
tarity of the information that can be obtained has the
potential to change our way of studying neuroinflamma-
tion, with implications for the management of several CNS
diseases.
Keywords Neuroinflammation  Magnetic resonance
imaging  Magnetic resonance spectroscopy 
Superparamagnetic iron oxides
Introduction
Neuroinflammation plays a critical role in the acute phases
of neuronal damage (e.g. to fight infections, and to remove
post-apoptotic cell debris), as well as in the subsequent
repair processes, including neurogenesis, oligodendrogen-
esis, and axonal sprouting [1].
In full-blown neuroinflammation, the activation of
microglia, the brain-resident macrophages that are the
initial responders to tissue damage, is generally accompa-
nied by blood–brain barrier (BBB) breakdown, release of
biohumoral inflammation mediators, such as cytokine and
chemokine, and by blood-borne leukocyte infiltration.
These phenomena result in the release, in the local
microenvironment, of oxidative and nitrosative products by
machrophages, microglia and astrocytes, and in the pro-
duction of excitotoxic metabolites, causing tissue damage.
Beside intense inflammatory reactions, such as those
that accompany stroke or acute inflammatory conditions
(e.g. multiple sclerosis relapses), also a prolonged, milder
inflammatory response, mainly associated with microglial
activation, can result in a damage to the brain cells, which
in turn can promote a reactivation of neuroinflammation,
providing a possible basis for the reciprocal reinforcement
of neuroinflammatory and neurodegenerative phenomena
[2].
Of note, neuroinflammation seems also to accompany
the neuronal activity under physiological conditions, rep-
resenting a tool to modulate the metabolic demands in
response to the physiological variations of neuronal net-
work activity. Indeed, the term ‘‘neurogenic inflamma-
tion’’, classically associated with the capacity of sustained
neuronal activity to trigger inflammatory reactions in
peripheral tissues [3], has recently been extended to
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encompass the inflammatory reactions within the CNS that
can be triggered by similar mechanisms [4].
Neurogenic neuroinflammation is postulated to have a
physiological role, possibly allowing the CNS to cope with
increased metabolic demands deriving from increased
computational activities, or promoting regeneration. How-
ever, an excessive duration of sustained neuronal activity
(such as in chronic pain or in psychological stress) or an
excessive extent of sustained stimulation (such as in
epileptic seizures) may render this mechanisms maladap-
tive, resulting in neuronal damage.
Several aspects of neuroinflammation can be studied by
MRI (Fig. 1), using a heterogeneous host of approaches
(Table 1) that allow to probe the mechanisms underlying
the brain/immune interaction at the level of vascular, cel-
lular, and interstitial compartments.
In this review, MRI methods that have been applied to
assess neuroinflammatory phenomena in preclinical and
clinical studies are described, grouped according to the
probed neuroinflammatory processes. MRI methods that
study endothelial activation, BBB permeability alterations,
intercellular compartment modifications, and immune cell
trafficking are thus reported. In addition, MR spectroscopy
(MRS) markers of glial activation and of immune cell
activity, suitable to monitor neuroinflammatory phenom-
ena, are summarized.
For each technique, the main advantages and limitations
are discussed in view of their potential clinical
exploitation.
BBB breakdown
The study of BBB integrity represents the most diffuse
approach to the assessment of the immune response in the
brain using MRI, given the ready availability in clinical use
of contrast agents that can effectively probe it.
It should be here noted that, although BBB permeability
alterations may in principle not be needed to define the
presence of neuroinflammation [5], most neuroinflamma-
tory stimuli primarily affect BBB integrity, and when any
of the several BBB constituents fails, almost invariably
neuroinflammation and neurodegeneration ensue [6].
Consequently, although the assessment of BBB perme-
ability does not detect/monitor neuroinflammation ‘‘per
se’’, it represents a sensitive clinical tool in pathologies
with neuroinflammatory components.
Alterations of BBB, ranging from hyperpermeability to
a widespread disruption of tight junction complex assem-
bly [7], allowing blood-born leukocytes extravasation [8],
occur in several physiological and pathologic conditions.
Foci of complete BBB disruption are generally present in
infectious diseases, such as in meningitis and encephalitis
[9], or in the active phases of multiple sclerosis (MS) [10].
However, milder permeability changes, not associated with
leukocyte trafficking, can also occur in pathologies not
primarily linked to neuroinflammation, such as cerebral
small vessel disease, diabetes [11], Alzheimer’s disease
[12], or even in association with normal aging [13], pos-
sibly as a consequence of subtle chronic neuroinflamma-
tory phenomena that accompany these conditions.
Contrast-enhanced MRI (CE-MRI), based on the use of
contrast media containing gadolinium, is the most com-
monly used non-invasive imaging method to assess BBB
alterations in both clinical and preclinical studies [14].
CE-MRI takes advantage of the intravascular compart-
mentalization in the brain, under normal conditions, of Gd-
chelates, which do not pass the intact BBB. In clinical
settings, CE-MRI is generally performed by acquiring T1-
weighted images several minutes following i.v. adminis-
tration of contrast medium, to reveal regions of reduced T1
(appearing bright on T1-weighted images) due to contrast
media extravasation in the presence of BBB breakdown.
Although very recent reports of signal changes in deep
gray matter structures may indicate a long-term retention of
Gd from previous MRI CE-MRI studies [15, 16], at least
when using linear molecules [17, 18], Gd-chelates in
clinical use have a very favorable safety profile, allowing
for repeated administrations, at least in patients with nor-
mal renal function.
A typical application of CE-MRI is the monitoring of
inflammatory activity in MS (Fig. 2). The possibility to
simultaneously assess ongoing inflammatory activity (by
contrast-enhancement detection), along with accumulated
lesion load (by T2w lesion segmentation) and neuronal loss
(by segmentation of normal brain tissues) [19], has ren-
dered conventional CE-MRI the mainstay in clinical trials
as surrogate biomarker for monitoring treatment response
in MS.
Note that segmentation methods for measurement of MS
lesion load and brain atrophy, although linked to sequelae
of inflammatory phenomena, are not being discussed in this
review, which is focused on methods that target active
inflammatory phenomena.
Alternatively, dynamic acquisition of MR sequences
sensitive to Gd concentrations, during the i.v. bolus
administration of contrast media (dynamic CE-MRI),
coupled with appropriate modeling strategies, has been
used to quantitate regional vessel permeability, assessing
cerebral blood flow and BBB permeability simultaneously
[20, 21].
Different algorithms have been developed to assess the
trans-capillary leakage of the contrast media molecule,
typically estimated in terms of forward volumetric transfer
constant (Ktrans), which is, however, also affected to a
variable extent by blood flow [22].
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To disentangle blood flow and vessel permeability,
allowing to measure selectively the trans-capillary perme-
ability in terms of Permeability-Surface area product (PS),
several methods have been developed, which take advan-
tage of the simultaneous measurement of CBF and Ktrans
allowed by DCE-MRI, provided sufficient temporal and
spatial resolution are obtained with appropriate sequences.
These methods are based on the use of a more complex
modeling (e.g. adiabatic approximation to the tissue
homogeneity [23]), coupled to a two-compartment
exchange model [24], and have not found large application,
partly because of the requirements they impose on scanner
hardware. More recently, it has been proposed to incor-
porate in the modeling the blood flow measured using
Fig. 1 Main neuroinflammatory mechanisms probed by MRI. Mod-
ifications of the neurovascular unit include alterations of the BBB
permeability, associated with overexpression of adhesion molecules,
which induce blood-borne monocytes to arrest and crawl along the
endothelium, crossing it by diapedesis along loosened intercellular
junctions. Machrophage and microglia activation results in increased
MPO activity and lactate accumulation in the interstitium, along with
the presence of cellular debris resulting from cell damage due to
oxidative and excitotoxic phenomena
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arterial spin labeling (an MRI technique for CBF mea-
surement available on most scanners, which can be
acquired prior to the DCE-MRI acquisition), to calculate
flow-corrected PS maps [25].
In addition to post-processing differences, variability of
scanner/sequence performance and of acquisition parame-
ters contribute to a lack of comparability of permeability
values obtained in different centers. Consequently, despite
the relative maturity of dynamic CE-MRI methods, and the
potential interest of permeability measures to monitor
neuroinflammation, the heterogeneity of the approaches
currently hinders inter-study comparability, thus limiting
the impact of available results and their utility to under-
stand the role of vessel permeability alterations in disease
pathophysiology [20, 26].
Adhesion molecules
Adhesion, the first step in the migration of blood-borne
leukocytes to the inflammation site, is mediated through
interaction of leukocyte integrins with molecules exposed
by endothelial cells, such as selectins (e.g., P- or E-se-
lectin), or adhesion molecules including vascular cell
adhesion molecule 1 (VCAM-1), intercellular adhesion
molecule 1 (ICAM-1), or platelet endothelial cell adhesion
molecule 1 (PECAM-1). Following adhesion, monocytes
transmigrate through the vessel wall by diapedesis and
migrate along cytokine gradients toward the site of
inflammation [27].
Antibodies against several of these adhesion molecules
have been conjugated to superparamagnetic particles of
iron oxide, which exhibit strong T1 and T2* relaxation
effects, typically stronger than Gadolinium chelates [28],
and can be visualized by suitable MR sequences.
Following different chemical routes for the synthesis
[29], superparamagnetic iron oxide nanoparticles of a
large range of sizes can be obtained, which affect their
biodistribution and relaxometric properties. In addition,
as these properties are largely conditioned by the effec-
tive size of the particles (which in turn varies depending
on their hydratation state [30]), the hydrodynamic
diameter is generally considered when classifying these
colloids.
Table 1 Main neuroinflammatory phenomena that can be assessed using MRI and/or MRS, with corresponding study techniques and stage of
development of the technique
Neuroinflammatory phenomena MRI/MRS technique Development stage
BBB permeability Dynamic contrast-enhanced MRI Clinical
Endothelial activation USPIO-labelled antibodies against surface molecules Investigative
Blood-borne cell migration Iron oxide colloids to track phagocytic cells
Non-specific labeling
In-vivo labeling Pilot clinical studies
Ex-vivo labeling Preclinical
Iron oxide-labeled antibodies against immune cells epitopes Investigative
Myeloid/glial cells activation Myeloperoxidase-activated contrast media Investigative
Spectroscopy ? Creatine Clinical
Spectroscopy ? Myoinositol Clinical
Interstitial modifications
Macromolecular composition Magnetization transfer Clinical
Lactate accumulation Spectroscopy ? Lactate Clinical
Cell debris accumulation Spectroscopy ? Choline (cell membranes turnover) Clinical
Cell debris accumulation Spectroscopy ? Lypids/macromolecules Clinical
Vasogenic edema Diffusion ? ADC/FA Clinical
Sequelae
Demyelination Diffusion ? Radial diffusivity Clinical
Neuronal loss Spectroscopy ? NAA (neuronal loss/dysfunction) Clinical
Axonal loss Diffusion ? Axial diffusivity Clinical
Axonal loss Conventional MRI segmentation ? Black holes load Clinical
Demyelination/gliosis Conventional MRI segmentation ? T2w lesion load Clinical
Investigative preliminary proof-of-concept studies have demonstrated in vivo sufficient sensitivity and specificity, Preclinical used in preclinical
studies to monitor disease progression and/or drug effect in neuroinflammatory conditions, but no human studies have been carried out, Pilot
clinical studies preliminary human studies are available, Clinical routinely used as a clinical tool, or employed as a biomarker in clinical trials
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Accordingly, iron oxide particles can be divided into
four subgroups (modified by [31]):
– Monocrystalline Iron Oxide particles (MNIO, hydro-
dynamic core\20 nm)
– Ultrasmall SuperParamagnetic Iron Oxide particles
(USPIO, 20 nm\ hydrodynamic core\ 50 nm)
– SuperParamagnetic Iron Oxide particles (SPIO,
50 nm\ hydrodynamic core\ 1 lm)
– MicroParticles of Iron Oxide (MPIO 1 lm B hydro-
dynamic core)
Anti-VCAM-1 antibodies conjugated to 1 lm sized
micron particles of iron oxide (VCAM-MPIO) have been
demonstrated to specifically accumulate in the site of
intracerebral injection of IL-1b [32], as VCAM-MPIO
uptake was not present in control animals injected only
with normal saline vehicle and was blocked by pre-treat-
ment with anti-VCAM-1 blocking antibodies.
The same approach in the MCAO model of stroke has
shown a more extensive area of VCAM-MPIO uptake,
compared to diffusion alterations, suggesting that hypop-
erfused brain regions at risk for infarction upregulate
VCAM-1 [33, 34].
Specific uptake of anti-VCAM-1 antibody conjugated to
MPIO has been also demonstrated in mice with EAE [35,
36] (above what seen by BBB permeability studies), in a
pilocarpin model of seizure [37], in models of vascular
dementia [35], and in the APPPS1 model of Alzheimer
disease [35].
Other adhesion molecules expressed on endothelial
cells, which have been demonstrated to upregulate in
presence of inflammation, are the E- and P-selectins (or
Fig. 2 Axial, sagittal and coronal MRI slices (3 Tesla, Philips
Medical Systems, Eindhoven, The Netherlands) from a 3D FLAIR
sequence (upper row) and the corresponding sections from a post-Gd
T1-weighted volume (bottom), in a multiple sclerosis patient. A right
posterior paraventricular lesion shows peripheral incomplete rim of
contrast enhancement, consistent with BBB breakdown due to active
inflammatory phenomena. A punctate iuxtacortical left occipital
enhancing lesion is also present
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CD62E/P), which are targeted by sialyl Lewis X (sLex),
expressed on leukocytes.
Sufficient sensitivity and specificity for imaging sLex
has been achieved using a glyconanoparticle molecule
(GNP-sLex), which carries more than 100 sLex molecules
on the surface of a dextran-coated USPIO). GNP-sLex has
been used to image the expression of endothelial adhesion
molecules in MOG-induced EAE and in stroke in rats [38].
ICAM-1, a member of the immunoglobulin superfamily
expressed by the endothelial cells, fostering the adhesion of
the leukocytes to the endothelium, has also been targeted
using anti-ICAM-1 functionalized MPIO, which showed
sufficient sensitivity to image neuroinflammation in a
MCAO stroke model in vivo [39] and after radiation injury
[40].
Finally, both Gd- and USPIO-labeled MRI agents have
been developed to target Integrin avb3, an adhesion
molecule expressed on endothelial cells, macrophages, and
platelets [41], although their use has been so far limited to
the study of tumor angiogenesis.
Although presently no imaging studies of overexpres-
sion of the adhesion molecules in the human brain are
available, the efficacy of therapeutic strategies based on the
blockage of adhesion molecules in neuroinflammatory
diseases, exemplified by the success of this approach in MS
[42], is boosting the efforts for translation to the clinical
ground of these methods.
However, before the MR imaging of adhesion molecule
can gain the clinical arena, several shortcomings must be
overcome, including safety issues related to the coating of
MPIOs, which are not biodegradable, and for which
potential specific side effects (related to the endothelial
inflammation triggered by their binding to the target
molecules) should also be fully excluded.
Cellular immune response
The main components of the cellular immune response in
the brain are constituted by two groups of cells, both
derived from the hematopoietic stem cells through two
radically different paths. While the microglia, the resident
macrophages of the CNS, originate in the yolk sac, the
other mononuclear cells participating in the immune
response originate in the bone marrow. Non-microglial
mononuclear cells with phagocytic properties involved in
the immune response include the perivascular, choroid
plexus, and meningeal macrophages, along with the cir-
culating monocytes, which leave the capillaries to reach the
CNS tissues under inflammatory conditions [43].
Recent advances in the design of contrast materials
currently allow MRI to afford sufficient sensitivity to track
the behavior of these cells in vivo, by labeling them with
superparamagnetic particles, which provide the possibility
to track single cells loaded with single MPIO particles
using MRI [44].
In general, the larger SPIO molecules have a shorter
half-life in the blood (\10 min in humans [45]) compared
to the smaller USPIOs, due to the more efficient removal of
these particles from the blood by the reticulo-endothelial
system. However, also the coating material and the surface
charge of the particles have a significant role in deter-
mining their fate and biodistribution, so that the behavior,
in terms of labeling efficiency, can still be very different
within the same subgroup of molecules, despite their
similar size.
Beside the intrinsic relaxometric properties of the
molecules, their effect on the MRI signal intensity is
modified by their compartmentalization. In particular, the
sequestration of iron nanoparticles in the reticuloendothe-
lial cells dramatically reduces the T1 relaxivity while
enhancing their T2/T2* relaxivity [31]. Accordingly,
techniques for detecting the cells labeled using these par-
ticles have generally focused on gradient-echo sequences,
exploiting T2* contrast to allow detection with high sen-
sitivity of their presence in monocytes/machrophages, to
track their fate in inflammatory sites, where their accu-
mulation is detected as low-signal foci, owing to T2/T2*
shortening (Fig. 3). The high T2* relaxivity of SPIOs,
coupled to the use of highly sensitive T2*-weighted gra-
dient-echo sequences, has indeed allowed to track in the
mouse brain single cells loaded with SPIOs, following i.v.
injection [46].
Different strategies can be adopted to label circulating
monocytes with these particles to assess cell trafficking
from the blood to the neuroinflammation sites.
Cells can be loaded with iron oxide colloids taking
advantage of their natural phagocytic properties, either by
incubation of the cells in vitro with the selected colloid or
by direct i.v. administration of the SPIO suspension
(in vivo labeling).
Although uptake of SPIO and USPIO in mononuclear
cells causes a transient oxidative stress, it does not affect,
even at high iron loads, in vitro cell survival, proliferation,
mobility, and phagocytic properties [47, 48].
It is useful here to remember that iron oxide phagocy-
tosis is not a function restricted to a specific phenotype of
mononuclear cells. In particular, as part of a continuum of
mononuclear cells’ behavior [49], both pro-inflammatory
(so-called M1, typically induced by exposure to IFN-c and
TNF-a) and anti-inflammatory ‘‘M2’’ (induced by IL-4 or
IL-13) phenotypes share phagocytic properties.
As a consequence, both these phenotypes present a
sizeable uptake of colloids, although CD14?? CD16—
(typically ‘‘pro-inflammatory’’) monocytes have shown
in vitro more efficient phagocytic properties toward iron
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oxide nanocolloids, compared to CD14?? CD16? (anti-
inflammatory) monocytes, as tested with both SPIO and
MNIO [50].
In addition, an induction of a shift towards an anti-in-
flammatory phenotype following SPIO uptake has been
suggested [51].
Accordingly, non-specificity of these particles, as per-
taining to the pro- or anti-inflammatory phenotype of the
monocytes, must be taken into account when interpreting
the results of studies based on this approach to cell
labeling.
Alternatively, cells can be selectively labeled by
superparamagnetic particles functionalized with specific
antibodies.
In-vitro labeling through phagocytic cell properties
Advantages of in vitro labeling are the high load of iron per
cell that can be achieved using this approach, and the
specificity of the labeling (although in principle cell death
subsequent to i.v. administration can still result in the
presence of free iron colloids in the bloodstream).
Main in vitro labeling strategies included the use of
dextran-coated SPIO complexed to poly-L-lysine [52], the
incubation with protamine sulfate as transfection agent
[52]*, or electroporation [53].
Given the higher complexity of these strategies, com-
pared to the direct in vivo i.v. administration of super-
paramagnetic colloids, relatively less studies have been
carried out using this approach. However, using these
strategies, detection in the spinal cord of mice with
experimental allergic encephalomyelitis (EAE, a preclini-
cal model of MS) of lymph node cells sensitized with the
proteolipid protein antigen used for EAE induction [54], or
of myelin basic protein-specific T-lymphocytes [52],
labeled in vitro using SPIO, has been achieved on T2*-
weighted images.
Incubation of MNIO with spleen-derived mononuclear
cells in a mouse model of transient middle cerebral artery
occlusion has also been used, allowing to track blood-
borne inflammatory cells to the periphery of the infarction
[55].
In-vitro labeling strategies have been used so far only in
preclinical studies of neuroinflammation, although they
have been proved to be safe in humans [56], and have been
used to image cell migration to cutaneous inflammation
sites. Currently no studies of neuroinflammation in humans
are reported using this approach.
In-vivo labeling through phagocytic cell properties
The ability of the monocyte/macrophage cell population to
phagocytose in vivo nanoparticles has been used to label
these cells by i.v. injection of iron nanocolloids to track by
MRI cell migration following neuroinflammatory phe-
nomena in various rodent stroke models.
The labeling efficiency of iron nanocolloids following
i.v. injection is essentially a function of the phagocytic
potential of the cells. Among circulating cells, mainly
blood monocytes (and to a much lesser extent neutrophils)
show a significant uptake.
Lymphocytes are essentially not labeled using this
approach due to their low spontaneous phagocytic activity
and limited cytoplasmic volume.
Phagocytic cells typically reach the infarct core on days
2–4, coming from the periphery of the lesion, and leave by
1 week post stroke, a temporal pattern confirmed by
experiments carried out in the photothrombotic stroke
Fig. 3 Representative T2*-
weighted axial images (9.4
Tesla, Bruker, Billerica, MA)
acquired 24 h post-i.v. injection
of SPIO (60 nm hydrodynamic
diameter, Feraspin-R, Miltenyi
Biotec GmbH, Bergisch
Gladbach, Germany) in a PLP-
EAE mouse, injected at the
height of the symptoms, and in a
control animal. Multiple foci of
USPIO uptake are present in
both hemispheric white matter
and deep gray matter structures
of the EAE model in the right
hemisphere
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model (providing standardized localized infarct lesions
without penumbra) [57].
Bone-marrow cells labeling in chimeric organisms [58]
has shown that microglial activation precedes migration
from blood of machrophages.
In the transient MCAO stroke model in rats, USPIO
uptake has been shown in the infarcted region [59, 60], in
agreement with histology. In addition, peri-infarct USPIO
uptake and spread to the contralateral hemisphere has been
shown in the same model [61], again in agreement with
histology data.
Interestingly, at later time points a mismatch between
the presence at histology of macrophages and the lack of
USPIO labeling has been found in photothrombotic stroke
model, suggesting a lack of phagocytic activities at these
later time points.
Despite the advantages represented by the simplicity of
the in vivo labeling procedure, and by the lack of manip-
ulation of the mononuclear cells, which may allow a more
natural behavior of these cells, different potential con-
founding factors should be still kept in mind when inter-
preting results obtained using this approach.
In particular, somewhat conflicting results have been
reported when assessing the route followed by iron col-
loids, especially of smaller size, following i.v. injection, to
reach the inflammatory sites, where they are detected in
phagocytic cells at histology. Indeed the possibility that
these particles cross a damaged BBB independent of cell
trafficking, and are subsequently captured by resident
microglia, must be carefully considered. Enhancement
related to dextran-coated iron oxide nanocolloids has been
in fact shown following BBB disruption by freezing or by
osmotic shock, although in the latter case only MNIO
particles (20 nm) crossed the basement membrane, as
opposed to SPIOs (200 nm) [62], so that the size of the
particles seems to play a major role here.
Consistent with this pattern, USPIO enhancement is
seen already within hours after photothrombotic stroke, as
opposed to monocytes labeled in vitro with SPIO [63],
supporting the hypothesis of a non-specific uptake from
resident microglia, following diffusion made possible by
BBB disruption.
Mononuclear cell migration to the stroke site has been
studied also in humans using i.v. injection of iron
nanocolloids. USPIO injection 7 days after the stroke has
shown a similar pattern of USPIO uptake in the ischemic
region, interestingly unrelated to Gd-DTPA enhancement
[64, 65], thus suggesting, at least under these specific
clinical conditions, a relative independence of the colloid
uptake from the disruption of the BBB.
These same considerations apply to the EAE studies
carried out using nanocolloids, as early (within 1 h from
injection) uptake of USPIO has been shown in rats with
EAE in cerebellar regions, which are characterized by
extensive BBB breakdown detected at Gd-DTPA-enhanced
T1-weighted images [66], clearly pointing at extravasation
as uptake mechanism. However, foci of USPIO uptake
unrelated to BBB breakdown, and corresponding at his-
tology to phagocytic leukocytes clusters, have been shown
at later time points [67, 68].
In addition, in EAE the extension and intensity of
USPIO uptake correlated with phagocyte infiltration, and in
turn with demyelination and axonal loss [69], indirectly
suggesting a clinical relevance of the phenomena probed
by USPIO.
Of note, in interpreting these results, beside wash-in
mechanisms, the role of a possible wash-out of USPIO from
the brain, either by cell migration or free diffusion, typically
to cervical lymph-nodes, should also be considered [66].
Finally, a lack of a direct relationship between USPIO
uptake and DTPA-Gd enhancement has been shown [70]
also in MS patients, thus indicating a possible comple-
mentarity of the information provided by these two MRI
parameters.
All together, these data suggest a time-dependent
specificity of colloid uptake related to the simultaneous
presence of BBB breakdown (allowing the colloid to reach
freely the interstitial space) and of cells with phagocytic
activity (either resident or blood-borne), these conditions
being both present in the very early phases after stroke. At
later time points, the dissociation between BBB breakdown
and USPIO uptake suggests more specific mechanisms of
uptake, secondary to phagocytose of these molecules by
blood monocytes, which then cross an intact, or only
mildly permeable, BBB.
Specific leukocyte labeling
Direct in vivo labeling of immune cells, including CD4,
CD8, and machrophage-specific epitopes has been obtained
using USPIO-labeled antibodies [71], allowing the in vivo
imaging in mice of immune cell migration to the inflam-
mation sites in EAE and viral encephalitis.
However, although a superior specificity can be in
principle obtained using this approach, it must be still
considered that, despite their different origins [43], specific
markers are not currently available that allow to reliably
discriminate microglia from blood-borne inflammatory
cells reaching the site of inflammation so that superiority of
this approach compared to phagocytosis-based labeling
remains to be proved.
Leukocyte functional imaging
Gd-bis-5-HT-DTPA (MPO-Gd) is a molecule activated by
myeloperoxidase (MPO), a proinflammatory oxidative
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enzyme secreted by activated neutrophils and monocytes at
inflammatory sites. MPO’s effect on MPO-Gd results in its
oligomerization and increased binding to proteins, which
both determine a T1 effect, allowing its detection in T1-
weighted images [72, 73].
T1 shortening in neuroinflammation areas using this
molecule has been proved to be specific by its negativity in
a MPO-knockout stroke mice [74].
MPO-Gd has been used to assess neuroinflammation in
stroke [74] and EAE [75], as well as to detect neuroin-
flammation following treatment by oncolytic virus in a rat
model of glioma [76].
In EAE in particular, it has shown a higher sensitivity
compared to BBB integrity tracers (Gd-DTPA). Of note, a
MPO-inhibitor has been used as experimental drug in EAE
mice, showing a reduced inflammatory and demyelinating
phenomena in treated mice [75], suggesting a possible
specific role of this approach for specific patient stratifi-
cation and future therapy monitoring.
Overall, no fully satisfactory method to image leukocyte
migration in humans by MRI is currently available. While
in vivo cell labeling by i.v. injection of iron colloids suffers
from limited specificity, and only a few pilot studies of
neuroinflammation in MS and stroke have been reported,
no method to label specific leukocyte classes has reached
the clinical use, also due to safety issues that still need to be
addressed.
In vitro labeling, which allows specific labeling of
leukocyte subclasses, could also provide very high iron
loads allowing to achieve single cell detection, comparing
favorably with currently available nuclear medicine tech-
niques. However, no brain studies in humans are currently
available using this approach.
It should also be noted that MRI studies using leuko-
cyte-labeling techniques are not inherently quantitative.
Indeed, iron oxide colloids have been used so far in human
studies essentially as indicators of ‘‘on/off’’ phenomena,
such as inflammatory activity in MS lesions, a pathology
where the endpoint for therapies is the reduction of the
number of ‘‘active’’ plaques, instead of the reduction of the
overall ‘‘intensity’’ of the inflammatory activity.
Finally, these techniques do not allow in general to
compare the results over time, as several factors, not lim-
ited to the variable labeling efficiency of cells, may vary
significantly over time, independently from inflammatory
phenomena (e.g., changes in signal of the background due
to lesion evolution may change the detectability of USPIO
accumulation, especially if hemorrhagic phenomena are
present).
On the other hand, nuclear medicine methods for
leukocyte imaging which have been used to image neu-
roinflammation, such as leukocyte labeling by 99mTc or
18F-FDG, also suffer, beside the limited spatial resolution,
from several shortcomings. These include the presence of
non-specific signal from the radiolabel eluted from the cells
(a weakness common to the MRI techniques), or the lim-
ited timeframe for acquisition following the injection due
to the short half-life of isotopes used in PET and SPET
imaging.
Alterations of the interstitial tissue composition
Diffusion-weighted Imaging is a technique that exploits
MRI exquisite sensitivity to motion to provide maps of
the bulk motion of water molecules due to diffusion
phenomena in biological tissues [77], thus providing an
in-depth analysis of the microstructural features of the
tissue [78].
Selective diffusion reduction along specific directions
occurs in anisotropic tissues, such as the white matter, in
which diffusion is not equal in all directions, due to the
presence of impermeable or semipermeable walls, such as
parallel cell membranes and myelin sheaths [77].
The use of sequences probing water diffusion along six
or more diffusion directions allows to calculate a full dif-
fusion tensor (diffusion tensor imagig—DTI), providing a
full-3D description of the water diffusion properties. From
DTI, maps of the apparent diffusion coefficient (ADC) and
fractional anisotropy (FA) can be calculated [79]. ADC is
an estimate of the mean magnitude of water movement
(independent of the direction), while FA is an estimate
index of the anisotropy of water diffusion [77].
BBB permeability alterations invariably result in a
change in the interstitial space composition, with extrava-
sation of macromolecules and onset of vasogenic edema
[80], which in turn determines an increase in ADC and a
reduction in FA, readily detected by DTI.
Diffusion-weighted imaging has allowed to study the
presence and time course of vasogenic edema in several
neuroinflammatory conditions (e.g. infections, traumatic
brain injury, stroke, demyeliniating diseases), as well as the
mechanisms underlying its resolution [81].
More recently, post-processing algorithms have been
developed to derive, from theDTI data,maps of the diffusion
properties of tissues, removing the diffusion changes due to
the amount of free water in the voxel [82]. These methods
have allowed detecting and characterizing subtle diffusion
alterations, possibly linked to chronic inflammatory phe-
nomena, in the brain of schizophrenic patients [83, 84].
Additionally, DTI data allow calculating separately
maps of the diffusivity along the main axis of diffusion
(longitudinal diffusivity) and along the plane perpendicular
to this axis (radial diffusivity). Longitudinal diffusivity
reflects water motion along the axons, mainly dependent on
the presence and viability of axons, while radial diffusivity
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is considered influenced mainly by cellular barriers, and
thus essentially by the integrity of myelin sheaths [85].
Accordingly, changes in these two parameters are used
to assess the relative contributions of axonal loss and
demyelination in determining diffusion changes in the
brain in several human neuroinflammatory pathologies
(e.g. in MS [86]).
Alterations of the microenvironment in terms of
macromolecular composition and hydration state, resulting
from BBB permeability alterations and activation of
proinflammatory pathways in the brain, can be explored
also by magnetization transfer (MT) imaging, which
exploits the exchange of protons between the free water
and the macromolecule compartments [87].
MT is probed by acquiring a T1-weighted volume pre-
ceded by an off-resonance RF pulse that excites selectively
the protons bound to the macromolecules. Part of the
magnetization conferred to macromolecules is then trans-
ferred, through magnetization interactions (dipolar and
chemical exchange) to the pool of the ‘‘mobile’’ protons
(those of the free water in tissue) resulting in a reduction in
signal. MT is assessed quantitatively through the MT ratio
(MTR, the difference between the signals obtained with
and without the off-resonance RF pulse, divided by the
signal obtained in absence of the off-resonance RF pulse).
As MT depends on the relative presence of the two pools
in the voxel, changes in the water content due to inflam-
mation result in a change of MTR [88].
Although main studies using MTR to assess neuroin-
flammation have been carried out in MS [88], MT has
demonstrated to be sensitive also to more subtle neuroin-
flammatory phenomena, including the effects of systemic
inflammation on the brain both in preclinical studies [89]
and in humans [90].
Overall, both DTI- and MT-derived measures have
shown a significant sensitivity to occult brain damage in
MS. However, it should be highlighted here that both
these techniques are non-specific (being variously influ-
enced by axonal loss, BBB permeability alterations,
inflammatory cell infiltrate, and demyelination). As a
consequence, only few studies have included these mea-
sures when defining secondary endpoints in clinical trials
of new disease-modifying treatments for MS, and their
use in routine monitoring of MS patients is extremely
limited [91].
MRS markers of neuroinflammation
MRS studies of primarily inflammatory (e.g. MS) and
infectious diseases of the CNS suggest that neuroinflam-
mation can result in elevated levels of myo-inositol (mI, an
organic osmolyte present in glial cells, participating in
astrocyte volume regulatory mechanisms [92]) and cho-
line-containing compounds (Cho) [93].
mI, in particular, has been shown in vitro to be a
selective glial marker in rat brain tissue extracts [92], with
selective expression of mRNA for sodium-dependent myo-
inositol transporter in astrocytes [94].
mI increases, which have been detected both in the
active [95] and non-active phases of MS [96], are present
already in the early stages of the disease [97], and are not
limited to MS lesions, but involve also normal-appearing
white matter [98, 99].
Viral infections are also characterized by increased mI.
In particular, HIV? patients show increased mI [93], while
in chronic hepatitis C infection, a condition linked to
neuropsychological symptoms and cognitive impairment, a
significant increase in mI in basal ganglia has been shown
[100, 101], correlating to 11C-(R)-PK11195 uptake at
positron emission tomography, consistent with significant
microglial/brain macrophage activation.
Of note, MRS allows to simultaneously assess the
degree of neuronal dysfunction/loss, concurrent with (or
due to) neuroinflammation by measuring N-acetyl-aspartate
(NAA), a selective marker of mature neurons. Accordingly,
in all the above conditions NAA decreases have been also
monitored allowing to assess in an integrated manner the
relationship between neuroinfammation and neuronal loss
[93].
However, these changes are non-specific, as mI can be
elevated in non primary inflammatory conditions, such as
hyper-osmolar states (e.g. hypernatremia, renal failure, and
diabetes [102, 103]), as well as in alcohol-dependent
patients [104], possibly due to alcohol-induced hyper-
osmolarity.
Also body-mass index in obese [105] and non-obese
subjects [106, 107] correlates to mI levels, which in turn
demonstrates a strong relationship with white matter frac-
tional anisotropy [107], possibly reflecting an effect of
neuroinflammation on white matter microstructure.
Furthermore, mI increases with age in normal brain have
been demonstrated, possibly due to the simultaneous
presence of demyelination and glial proliferation [108].
On the other hand, increased choline has also been
detected in several non-primarily inflammatory brain dis-
orders, including brain tumors [109] stroke [110], epilepsy
[111], traumatic brain injury [112, 113], and HCV [100,
114]. In these pathologies, Cho increase has been variously
interpreted as reflecting in turn products of membrane
degradation, angiopathy, edema, or energy failure.
In summary, MRS has shown a sufficient sensitivity for
assessing neuroinflammatory disorders, and has been
applied in MS, neuroviral infections, the main markers of
active neuroinflammation being increased myo-inositol,
choline, and total creatine [93]. Although its limited
484 Clin Transl Imaging (2015) 3:475–489
123
specificity hampers its potential in terms of differential
diagnosis, suitable applications have been found for lon-
gitudinal monitoring, especially in neuroviral diseases,
while MRS-derived measures of neuronal loss (NAA
reduction) have shown a clear potential in terms of both
prognostic value and assessment of the effects of treat-
ments in MS [115].
Conclusion
With the growing interest in the role of neuroinflammation,
also in pathologies not traditionally considered as primarily
neuroinflammatory (e.g. Alzheimer’s disease [116] or
psychiatric disorders [117]), non-invasive techniques to
study in vivo the complex cascades of events involved in
different aspects of neuroinflammation are increasingly
required.
In MRI, the advantages represented by the large avail-
ability of the technique, and by the lack of exposure to
ionizing radiations, are coupled to the possibility to assess
simultaneously different features of neuroinflammation,
ranging from BBB breakdown and interstitial microenvi-
ronment changes, to cellular infiltration and gliotic reaction.
As a consequence, as more and more aspects of neu-
roinflammation become accessible to probing by MRI/
MRS, an increasing number of studies is carried out taking
advantage of the complementarity of the information pro-
vided by this technique.
However, especially when compared to nuclear medi-
cine techniques, that allow a sensitive and specific detec-
tion of microglial activation [2], specificity of the MRI
techniques remains an issue.
From this standpoint, a further advancement can be
expected following the recent introduction of hybrid PET/
MRI scanners, which allow to cross-correlate the different
datasets avoiding time-dependent variability.
Furthermore, the simultaneous acquisition of PET and
MRI allows to co-register easily and in an operator-inde-
pendent manner the PET, which lacks anatomical land-
marks when PET neuroinflammation tracers are used, with
the MRI.
In preclinical studies, the possibility to carry out longi-
tudinal studies assessing simultaneously perfusion, BBB
permeability, and infiltration from monocytes using MRI,
and microglial activation using PET, is expected to help
clarify the time course and the complex interactions of
inflammatory phenomena in primarily neuroinflammatory
diseases and in stroke.
In clinic, the accurate co-registration with structural
studies achievable with hybrid scanners can improve our
sensitivity when very limited tracer uptake is present,
provided it occurs consistently in the same anatomical
structure. To date, PET/MRI studies have been used to
demonstrate subtle but significant glial activation, corre-
lating with pain severity, in specific brain regions in
patients with chronic back pain [118] and in the motor
cortices and corticospinal tracts of patients with amy-
otrophic lateral sclerosis [119].
Despite the abovementioned limitations, in vivo neu-
roimaging methods help unraveling the multi-faceted role
of neuroinflammation in several CNS diseases, including
pathologies once considered exquisitely neurodegenera-
tive, and the currently ongoing transition from pre-clinical
to clinical applications of these techniques has the potential
to introduce significant changes in the management of
these diseases.
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